SLU-PP-332, a novel ERR agonist, mimics exercise by enhancing mitochondrial metabolism and muscle adaptation, offering potential in treating metabolic and cardiovascular disorders [PMID: 41850449], [PMID: 41688415]. Its structural optimization improves selectivity and efficacy as revealed by SAR analysis [PMID: 41850449].
SLU-PP-332, a novel ERR agonist, mimics exercise by enhancing mitochondrial metabolism and muscle adaptation, offering potential in treating metabolic and cardiovascular disorders [PMID: 41850449], [PMID: 41688415]. Its structural optimization improves selectivity and efficacy as revealed by SAR analysis [PMID: 41850449].
• SLU-PP-332 mimics exercise by activating ERR pathways, enhancing muscle metabolism [PMID: 41850449]. • Structural optimization improves SLU-PP-332's drug-like properties and ERR selectivity [PMID: 41850449]. • SLU-PP-332 increases oxidative muscle fibers and energy expenditure in mouse models [PMID: 41688415]. • Nine metabolites of SLU-PP-332 identified, crucial for its detection in doping control [PMID: 41588687].
SLU-PP-332 is gaining attention as an exercise mimetic due to its ability to activate estrogen-related receptors (ERRs), which play a crucial role in mitochondrial metabolism and exercise-responsive transcription [PMID: 41850449]. ERR agonists like SLU-PP-332 are under investigation for their potential to simulate the physiological effects of physical activity, offering new avenues for addressing metabolic and cardiovascular disorders [PMID: 41688415].
The exercise mimetic potential of SLU-PP-332 is linked to its structure and activity relationship (SAR), which, when optimized, shows improved physicochemical properties, selectivity for ERR subtypes, and metabolic stability [PMID: 41850449]. These developments have resulted in analogues that retain or exceed the transcriptional efficacy of the original molecule while overcoming some of its limitations.
In mouse models, SLU-PP-332 has demonstrated an increase in oxidative muscle fibers and energy expenditure, enhancing resistance against metabolic syndrome features like obesity and type 2 diabetes [PMID: 41688415]. Its benefits also extend to cardiovascular health, where it offers protection against heart failure by promoting fatty acid metabolism and mitochondrial function.
Metabolic studies have identified nine metabolites of SLU-PP-332, emphasizing the importance of understanding its biotransformation for anti-doping measures [PMID: 41588687]. This provides a pathway for developing methods to detect illegal performance enhancement in sports competitions.
The promising preclinical findings of SLU-PP-332 warrant further research, particularly in human clinical trials, to confirm its efficacy and safety in therapeutic settings. As it stands, much of the current evidence arises from animal studies and in vitro analyses, necessitating careful extrapolation to human scenarios.
By advancing our understanding of SLU-PP-332 through continued research, there is significant potential to develop novel therapies that harness the benefits of exercise without physical activity, targeting diverse health issues from metabolic disorders to age-related muscle atrophy.
This research briefing is based on the verified PubMed records linked in the References & Citations section below.
Ask PepBot any follow-up question about this topic. It knows every study, every protocol, every dosing detail.
Send this cited research summary to someone who is asking the same question.
Keep exploring
Mechanism, study context, and related research for SLU-PP-332
Browse every ChatPEP research guide
See side-by-side research comparisons